Trial Profile

Control Crohn Safe With Episodic Adalimumab Monotherapy as First Line Treatment Study

Status: Recruiting

Phase of Trial: Phase IV

Latest Information Update: 11 Sep 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Adalimumab (Primary)
Indications Crohn's disease
Focus Therapeutic Use
Acronyms CoCroS

Most Recent Events

06 Sep 2022 Planned End Date changed from 1 Sep 2024 to 1 Sep 2026.
22 Jul 2020 Planned End Date changed from 1 Sep 2023 to 1 Sep 2024.
22 Jul 2020 Planned primary completion date changed from 1 Dec 2022 to 1 May 2024.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com